Access to Information Requests Completed – December 2012

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of December 2012

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2011-00356	All ministerial correspondence regarding the issue of medical marihuana. (Jan 1, 2010 to Jun 21, 2011).	Disclosed in part	929
A-2011-00727	Briefing notes, reports and memos regarding prescription drug shortages and/or the supply of prescription drugs. (Sep 1, 2010 to Sep 20, 2011).	Disclosed in part	264
A-2011-00910	All documents pertaining to the expiration of the legislation and agreements governing the Canada Health Transfer in 2013-4. (Jan 1, 2011 to Oct 28, 2011).	Disclosed in part	44
A-2011-01037	Documents in the custody of the Minister of Health, the Deputy Minister of Health, the Assistant Deputy Minister of the Health Products and Food Branch, and its relevant directorates and/or divisions pertaining to Simian Foamy Virus (SFV) testing/retesting.	Disclosed in part	133
A-2011-01472	Memorandum to cabinet for Bill C-47 1996 (The Human Reproductive and Genetic Technologies Act).	Disclosed in part	18
A-2012-00030	Correspondence between the Minister of Health and the Minister of Indian (or Aboriginal) Affairs and Northern Development concerning the Food Mail Program and/or Nutrition North Canada. (Nov 1, 2008 to Mar 31, 2012).	All exempted	0
A-2012-00060	All documents from 2012 and 2011 within Health Canada files relating to the work of Canada Health Infoway's Growth and Innovation Working Group.	Disclosed in part	19
A-2012-00168	Information regarding the product Melatonin Slow Release, NPN 80014831 by Douglas Laboratories Canada.	Disclosed in part	36
A-2012-00194	All documents regarding a contract with the Lung Association. (Jan 1, 2011 to May 10, 2012).	Disclosed in part	890
A-2012-00195	All documents regarding the funding for the New Brunswick Lung Association (6549-04-2010/7650094 - Deliver a Public Education Campaign for Health Risks from Combined Radon and Tobacco Exposure). (Jun 4, 2010 to May 11, 2012).	Disclosed in part	387
A-2012-00252	User Manual for Pelvilace Biourethral Support System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	55
A-2012-00402	All documents funded under the Canada Brain Research Fund established in the 2011 federal budget. (Jan 1, 2009 to May 8, 2012).	Disclosed in part	15
A-2012-00601	Information regarding the product Novo-Norfloxacin by Novopharm Ltd.	Disclosed in part	273
A-2012-00616	All documents regarding InterNoise 2012 papers. (Jan 1, 2012 and Jul 19, 2012).	Disclosed in part	362
A-2012-00720	All documents relating to personal harm and injury caused by the drug ZOLOFT (sertraline hydrochloride), including all generic versions of this drug. (Jan 1, 2005 to Aug 8, 2012).	Disclosed in part	92
A-2012-00831	All correspondence with representatives of Physicians for a Smoke Free Canada. (Jan 1, 2011 to Aug 20, 2012).	Disclosed in part	1,994
A-2012-00903	All approved Product Monographs for the product Heparin by Baxter.	All disclosed	20
A-2012-00919	AERs for the product Avelox. Report numbers: 000427638, 000429402, 000429977, 000430521, 000431264, 000431823 and 000431921.	Disclosed in part	22
A-2012-00930	Health Canada's communications with (to) Metcalfe Reality regarding the Macdonald building, 123 Slater Street, Ottawa. (Jan 1, 2008 to Jun 30, 2010).	Disclosed in part	97
A-2012-00967	Any document received from any lawyer, legal representative, law firm, of a client or organization in regards to wind energy, noise, turbines, and health effects. (Oct 1, 2010 to Oct 31, 2012).	Disclosed in part	71
A-2012-00999	All briefing documents prepared for the Federal-Provincial -Territorial Health Ministers meeting on September 28, 2012 regarding tobacco.	Disclosed in part	111
A-2012-01069	All documents related to the government's decision to encourage kids under 18 to cap cell phone use (decision unveiled on October 4, 2011).	All disclosed	112
A-2012-01087	All briefing to the Minister about Establishment 38 and/or related XL Foods beef recall. (Sep 3, 2012 to Oct 29, 2012).	No records exist	0
A-2012-01099	Statistical information on counselling services provided under the Employee Assistance Program. (Mar 1, 2012 to Nov 13, 2012).	All disclosed	3
A-2012-01102	All briefing notes prepared for the Deputy Minister, the Minister of Health or her staff on the subject of soft drink regulation or taxation. (Jan 1, 2010 to Nov 13, 2012).	No records exist	0
A-2012-01103	AERs. Report numbers: 000378083 and 000352330.	Disclosed in part	2
A-2012-01104	List of all Canadian pharmaceutical companies conducting trials of pharmaceuticals outside of Canada and the locations of these trials.	No records exist	0
A-2012-01111	Information related to Minister Aglukkaq's office in Whitehorse, Yukon regarding the annual staffing costs for the office and how many people are employed there and the annual rental or leasing costs for the office.	Disclosed in part	1
A-2012-01124	Information regarding the product enoxaparin sodium by Novopharm Ltd.	All exempted	0
A-2012-01126	All emails sent or received by the Minister of Health and the Deputy Minister of health related to the National Aboriginal Health Organization (NAHO). (Jan 1, 2011 to Nov 19, 2012).	No records exist	0
A-2012-01128	All correspondence received from outside stakeholder groups on the subject of soft drink regulation or taxation. (Jan 1, 2010 to Nov 14, 2012).	No records exist	0
A-2012-01130	The overall number of current Licenses to Produce Cannabis (marihuana) that have been issued by Health Canada under the Marihuana Medical Access Program to recipients within the City of Surrey, British Columbia. (Oct 1, 2011 to Oct 31, 2012).	All disclosed	1
A-2012-01132	AER. Report number: 00411801.	Disclosed in part	2
A-2012-01133	AER. Report number: 00418233.	Disclosed in part	2
A-2012-01134	AER. Report number: 00406136.	Disclosed in part	2
A-2012-01136	AER. Report number: 00427006.	Disclosed in part	1
A-2012-01137	AER. Report number: 00442175.	Disclosed in part	1
A-2012-01138	AER. Report number: 00431864.	Disclosed in part	2
A-2012-01139	AER. Report number: 00437975.	Disclosed in part	1
A-2012-01140	AER. Report number: 00446910.	Disclosed in part	1
A-2012-01141	AER. Report number: 00447540.	Disclosed in part	1
A-2012-01142	AER. Report number: 00441259.	Disclosed in part	5
A-2012-01143	AER. Report number: 00426105.	Disclosed in part	2
A-2012-01144	AER. Report number: 00426128.	Disclosed in part	1
A-2012-01145	AER. Report number: 00426804.	Disclosed in part	10
A-2012-01146	AER. Report number: 00427289.	Disclosed in part	4
A-2012-01148	AER. Report number: 00427554.	Disclosed in part	1
A-2012-01149	AER. Report number: 00427816.	Disclosed in part	11
A-2012-01150	Summary Basis of Decision regarding the product BIPHENTIN, DIN 02277131 by Purdue Pharma.	No records exist	0
A-2012-01152	AER. Report number: 00429458.	Disclosed in part	4
A-2012-01154	AER. Report number: 00442039.	Disclosed in part	1
A-2012-01166	Most current job descriptions' including job titles and classifications' of all positions held in the Cabinet and Parliamentary affairs division.	All disclosed	200
A-2012-01168	All call-ups/Contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Translation Services. (Sep 22, 2012 to Nov 21, 2012).	Disclosed in part	80
A-2012-01214	AERs for the product DEXILANT (dexlansoprazole). Report numbers: 000430911 and 000444155.	Disclosed in part	3